Compare MHH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | TIL |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 74.7M |
| IPO Year | 2008 | 2021 |
| Metric | MHH | TIL |
|---|---|---|
| Price | $5.58 | $8.37 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 8.9K | ★ 19.4K |
| Earning Date | 05-15-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $191,371,000.00 | N/A |
| Revenue This Year | $2.93 | N/A |
| Revenue Next Year | $8.93 | N/A |
| P/E Ratio | $117.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.51 | $5.67 |
| 52 Week High | $9.96 | $42.75 |
| Indicator | MHH | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.17 | 47.38 |
| Support Level | $5.52 | $8.07 |
| Resistance Level | $8.00 | $9.05 |
| Average True Range (ATR) | 0.45 | 0.48 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 16.73 | 51.37 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.